Blood test could end Trial-and-Error for arthritis patients
NCT ID NCT07150000
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 32 times
Summary
This study is testing a new blood-based test that aims to predict which medication will work best for each person with an autoimmune rheumatic disease. Researchers will take a blood sample and use it to measure how a patient's immune cells respond to different drugs. If successful, this could replace the current trial-and-error approach, helping patients get effective treatment faster and with fewer side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GOUT ARTHRITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Hospital, Bonn
RECRUITINGBonn, North Rhine-Westphalia, 53127, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ex vivo diagnostic assay using patient blood cells
What this could lead to
If successful, this test could help doctors choose the right medication for each patient from the start, reducing side effects and speeding up relief.
What could go wrong
This is an early-stage study with only 120 participants. The test may not accurately predict responses for all patients or diseases, and further validation is needed.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.